Key Players are Illumina (U.S.), Life Technologies (Thermo Fisher Scientific) (U.S.), CLC bio (Denmark) (acquired by QIAGEN), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.), and DNASTAR (U.S.).
(PRWEB) February 13, 2015
The next generation sequencing market is witnessing significant growth across the globe due to factors such as decreasing costs, improved turnaround time, increase in number of applications and replacement of micro-array applications by next generation sequencing (NGS). The key players are focusing on providing innovative products which are technologically advanced. Owing to this companies focus on partnerships, collaborations, new product launches and acquisitions in order to attain a leadership position in the market.
The global next generation sequencing (NGS) market will be worth $2.5 billion by the end of 2014 and is poised to reach $8.7 billion by 2020 at a CAGR of more than 20.0%.
The next generation sequencing report covers the market for pre-sequencing, sequencing platforms and bioinformatics tools and services. The NGS pre-sequencing (sample –preparation) segment represents a promising area in the overall market owing to the need for automation and standardized solutions for sample preparation. The market for sequencing platforms has been very dynamic. Some revolutionary platforms like GA IIx (Illumina) and SOLiD Series (Life Technologies) have taken a setback and newer platforms like HiSeq X Ten, NextSeq 500 and MiSeq are gaining market dominance. The next generation sequencing bioinformatics market comprises of software, workbenches and services for the interpretation and analysis of data generated by sequencers, representing a lucrative market owing to better user interface and flexibility when compared to open-source tools.
The report also covers the market by applications, including drug discovery, clinical diagnostics, genomics, and proteomics. Along with large research and academic institutions that serve as a key end-user for the next generation sequencing market. NGS technologies are recently being developed for use in clinical set-ups and presently much of the NGS effort is focused on cancer.
For More Details @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=546
Another major revenue generating market will be NGS services market which is estimated to grow at a CAGR of 24.0% by 2020. This can be attributed to the growing demand in diagnostics and pharma/biotech sectors. In diagnostics the growth will be driven by increasing cases of oncology and neonatal diseases. Moreover the possible reimbursement for diagnosis through NGS will also boost the market 2015 onwards. Pharma/Biotech companies also look forward to outsource their NGS related services to focus on core competencies. Yet research centers and academic institutes contribute the highest to the services market.
Speak with Research Analyst @ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=546
Targeted resequencing, RNA-Seq and Exome Sequencing are the top three applications of NGS primarily due to their low cost and time-saving ability. These segemnets will also be the top three fast growing segments in the coming years.
The global NGS market is highly consolidated with top two players Illumina and Thermo Fisher (Life Technologies) occupying more than 90% of the pie (2013). Illumina led the market with its flagship NGS platforms such as HiSeq Series, GA IIx and MiSeq. In 2014, it launched two new platforms HiSeq X Ten and NextSeq 500 which are poised to grow at CAGR of more than 20% in the coming years. It also provides reagents like TruSeq sample preparation kits, TruSeq SBS Sequencing kit and other sequencing consumables. It also offers sequencing services such as whole genome sequencing, human whole exome, de novo sequencing, custom targeted resequencing, gene expression using random primed RNA sampling and other related services. It also has a global presence with more than 50% of revenue generated from the U.S. and more than one-fourth from Europe. The market share of Illumina is estimated to increase by 2020, driven primarily by MiSeq, HiSeq X Ten and NextSeq 500 platforms, sales of consumables and increased service contract revenue as a result of growing installed base of instruments.
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology